drugset / Trial / NCT01220999

A Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer

NCT01220999

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This was a Phase 1, open-label, single-center study of CS-1008, an immunoglobulin G subclass 1 (IgG1) humanized monoclonal antibody, in subjects with advanced colorectal carcinoma who had received ≥ 1 prior chemotherapy regimen for metastatic disease. Primary study objectives were to determine the influence of the CS-1008 dose on the biodistribution, pharmacokinetics (PK) and tumor uptake of radiolabeled CS-1008 following a single infusion and following continuous sequential doses of CS-1008. Secondary objectives were to evaluate changes in tumor metabolism, antitumor response, and changes in serum apoptosis biomarkers and tumor response markers following treatment with CS-1008.

Timeline

Start
2010-10-12
Primary completion
2012-06-27
Completion
2012-06-27

Drugs

EvaluationDrugModalityDoseRoute
Subject tigatuzumab Monoclonal antibody 2 mg/kg Intravenous

Indications